Realise the Commercial Potential of Gene Therapies
2020 is the year that gene therapies have come into their own. After decades of unfulfilled potential, this space is gaining tangible momentum, particularly in addressing the significant unmet need in a range of rare diseases.
Gene Therapy for Rare Disorders Europe is the uniquely focused conference uniting industry leaders to discuss the late-stage challenges that need to be overcome to deliver more gene therapies to market.
Rather than early stage basic science, this meeting is solely devoted to addressing the latest clinical, manufacturing, regulatory and commercialization challenges facing this rapidly evolving field. This is a comprehensive guide to define your commercial path forward.
Register your interest for updates on the 2020 meeting.
“Best conference of the year for gene therapy companies to understand how our industry is tackling the challenges of pioneering the development of our advanced therapy products.”
"This is one of the best meetings I have ever attended. It was a crash course in everything AAV from manufacturing through clinical applications and commercialization. The quality of the speakers was top notch, networking was very efficient and the organization impeccable."
|* Based on Gene Therapy for Rare Disorders US 2019|